PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

PLIANT THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.90−0.00 (-0.13%)

Close on Oct 19, 2026

Market cap: $55.65M
P/E (TTM): –
Dividend yield: 0.00%

PLIANT THERAPEUTICS, INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	45	73	65	34	52	51	86	61
Short-Term Investments	145	285	431	298	149	226	17	–
Cash & Short-Term Investments	191	357	496	331	201	277	103	61
Receivables	–	–	0	1.98	2.00	9.28	7.05	–
Prepaid Expenses & Other	4.46	6.54	11	7.06	6.76	4.50	1.74	–
Total Current Assets	196	362	506	340	209	291	112	–
Property, Plant & Equipment	2.94	5.53	3.57	4.49	4.61	4.32	4.08	–
Gross Property, Plant & Equipment	14	16	12	11	9.63	7.81	6.27	–
Accumulated Depreciation	-11	-11	-8.68	-6.84	-5.02	-3.49	-2.19	–
Operating Lease Right-of-Use Assets	24	27	1.21	5.42	6.33	0	–	–
Other Long-Term Assets	0.39	0.44	0.39	0.39	0.84	0.45	3.09	–
Total Assets	225	397	512	351	221	296	119	–
Accounts Payable	0.48	5.96	4.53	1.58	2.97	2.02	1.25	–
Accrued Expenses	9.63	12	10	8.66	12	9.58	6.92	–
Current Portion of Leases	1.45	0.54	1.32	2.46	1.87	0	–	–
Total Current Liabilities	16	33	29	24	17	12	8.17	–
Long-Term Leases	28	29	0	3.43	5.33	0	–	–
Operating Lease Liabilities	29	30	1.32	5.89	7.19	0	–	–
Other Long-Term Liabilities	–	–	–	–	0	0.87	0.91	–
Total Liabilities	44	93	39	37	22	12	9.08	–
Preferred Stock	0	0	0	0	–	–	–	–
Common Stock	0.01	0.01	0.01	0.01	0.00	0.00	0.00	–
Additional Paid-In Capital	1,041	1,014	973	654	414	401	0	–
Retained Earnings	-859	-710	-500	-338	-215	-118	-76	–
Comprehensive Income & Other	-0.02	0.32	0.35	-1.96	-0.20	-0.03	0.00	–
Shareholders' Equity	181	304	474	313	199	283	-76	-71
Total Equity	181	304	474	313	199	283	-76	-71
Total Liabilities & Equity	225	397	512	351	221	296	119	–
Shares Outstanding(shares)	61	61	60	49	36	36	1.85	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -61.5%

Financial strength

Current ratio: 9.90
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 151.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.38
Dividend yield: 0.00%